Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the effectiveness and safety of the investigational drug SB683699 in
treating patients with relapsing multiple sclerosis (MS), using data from magnetic resonance
imaging (MRI) scans as the main measure.